Clearmind Medicine Schedules Shareholder Meeting for Jan 6, 2025
Ticker: CMND · Form: 6-K · Filed: Dec 6, 2024 · CIK: 1892500
Sentiment: neutral
Topics: shareholder-meeting, proxy-materials, corporate-governance
Related Tickers: CMND
TL;DR
Clearmind Medicine (CMND) holding shareholder meeting Jan 6, 2025. Record date Nov 28, 2024.
AI Summary
Clearmind Medicine Inc. filed a 6-K report on December 6, 2024, providing proxy materials for its Annual and Special Meeting of Shareholders scheduled for January 6, 2025. The record date for determining eligible shareholders was November 28, 2024.
Why It Matters
This filing informs shareholders about an upcoming meeting where key corporate decisions will be made, impacting the company's future direction and governance.
Risk Assessment
Risk Level: low — This is a routine filing providing notice of a shareholder meeting and related proxy materials, with no immediate financial or operational changes disclosed.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer of the 6-K report
- January 6, 2025 (date) — Date of the Annual and Special Meeting of Shareholders
- November 28, 2024 (date) — Record date for determining shareholders entitled to vote
FAQ
What is the purpose of the 6-K filing?
The 6-K filing contains proxy materials for Clearmind Medicine Inc.'s Annual and Special Meeting of Shareholders.
When is the Annual and Special Meeting of Shareholders scheduled to take place?
The meeting is scheduled for Monday, January 6, 2025.
What was the record date for determining shareholders eligible to attend the meeting?
The board of directors fixed November 28, 2024, as the record date.
Is Clearmind Medicine Inc. a US or foreign private issuer?
The filing indicates Clearmind Medicine Inc. is a foreign private issuer and files annual reports under cover of Form 20-F.
Where is Clearmind Medicine Inc. located?
The company's principal executive offices are located at 101 – 1220 West 6th Avenue, Vancouver, British Columbia.
Filing Stats: 320 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-12-06 17:00:08
Filing Documents
- ea0223734-6k_clearmind.htm (6-K) — 13KB
- ea022373401ex99-1_clearmind.htm (EX-99.1) — 616KB
- ea022373401ex99-2_clearmind.htm (EX-99.2) — 2KB
- ea022373401ex99-3_clearmind.htm (EX-99.3) — 2KB
- ea022373401ex99-4_clearmind.htm (EX-99.4) — 1KB
- ea022373401ex99-5_clearmind.htm (EX-99.5) — 4KB
- ex99-2_001.jpg (GRAPHIC) — 641KB
- ex99-2_002.jpg (GRAPHIC) — 707KB
- ex99-3_001.jpg (GRAPHIC) — 778KB
- ex99-3_002.jpg (GRAPHIC) — 710KB
- ex99-4_001.jpg (GRAPHIC) — 433KB
- ex99-5_001.jpg (GRAPHIC) — 12KB
- ex99-5_002.jpg (GRAPHIC) — 15KB
- 0001213900-24-106541.txt ( ) — 5177KB
Financial Statements Request Form
Financial Statements Request Form 99.5 Abridgement Certificate 2 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: December 6, 2024 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3